γ-Aminobutyric Acid (GABA): Ingredient Quantity Labeling Standards and Cross-Border Compliance — A Comprehensive Analysis

---

Abstract

γ-Aminobutyric acid (γ-Aminobutyric Acid, GABA, CAS No. 56-12-2) is a non-protein amino acid that occurs naturally in plants, microorganisms, and mammalian brain tissue, and has also been detected in fermented foods such as kimchi, natto, and aged cheese. As Japan's "Foods with Function Claims" system has taken hold, GABA ingredients have attracted growing attention in the health food sector, and products with GABA as a primary ingredient have flowed in large volumes into cross-border markets in China, Southeast Asia, and North America.

GABA is not a pharmaceutical drug, however, and the information carried on its labels must be strictly distinguished from drug prescribing information. The regulatory status of this ingredient, daily intake ceilings, and permissible claims differ materially across jurisdictions. This paper provides a systematic review across three dimensions — ingredient quantity labeling standards, label compliance frameworks, and cross-border purchase verification methods — in order to supply actionable reference guidance for manufacturers, importers, and end consumers. All regulatory provisions cited herein are based on official documents publicly released as of the date of writing; readers should independently verify their continued validity.

---

I. GABA Ingredient Quantity Labeling Standards

1.1 Japan: Quantification Requirements Under the Food Labeling Standards

Japan's current labeling regulatory framework centers on the *Food Labeling Standards* (Consumer Affairs Agency Notification), which entered into force in 2015, and is supplemented by the *Health Promotion Act* and the *Act against Unjustifiable Premiums and Misleading Representations* in governing health food labels.

Mandatory Disclosure of Daily Intake

Any food sold for the purpose of "maintaining and improving health" must state, in a prominent position on the label, the recommended daily intake and the GABA content (unit: mg) corresponding to that intake. The *Foods with Function Claims* (Kinōsei Hyōji Shokuhin) system, in force since 2015, further requires that where a company intends to include a function-related claim for GABA on its label, a notification must be submitted to the Consumer Affairs Agency. The notification dossier must include:

• A quantitative analysis report for GABA in the ingredient (high-performance liquid chromatography, HPLC, or a method of equivalent sensitivity);
• Batch-to-batch content consistency data (the coefficient of variation, CV, is generally required to be ≤15%);
• The labeled value must be set as the guaranteed lower bound of actual measured values — i.e., the labeled quantity must not exceed the lowest measured quantity across batches.

Filed Examples for Foods with Function Claims Involving GABA

The Consumer Affairs Agency's publicly accessible Foods with Function Claims Database (FLD) has accumulated hundreds of GABA-related notifications, each identifiable by notification number and labeled content, all searchable record by record through the official search portal (fld.caa.go.jp). The "Quantity of Functional Ingredient" (Kinōsei Kanyū Seibun-ryō) stated in the notification summary constitutes the quantitative basis consumers may rely upon. Once a notification has been accepted and published, companies may not label actual products with a GABA content lower than the notified quantity.

General Health Foods (Non-Notified)

GABA products for which no Foods with Function Claims notification has been filed must follow the nutrient labeling schedule of the Food Labeling Standards, with GABA listed at the end of the nutrition facts panel under "Other Ingredients" (Sonota no Seibun), in units of mg/day or mg/tablet (capsule). Any exaggerated or false quantity representation may be subject to administrative sanction under Article 5, Paragraph 1 of the Act against Unjustifiable Premiums and Misleading Representations (misleading representation as to superiority).

1.2 China: Quantity Management Under the Novel Food Ingredients Framework

The National Health Commission (formerly the Ministry of Health) approved GABA as a novel food ingredient (formerly "new resource food") in Announcement No. 12 of 2009, establishing the following key parameters:

Labeling Requirements

Products using GABA as an ingredient must state on the label:

• 1. The ingredient name: γ- (γ-Aminobutyric Acid) — labeling the English abbreviation "GABA" alone without the Chinese name is not permitted;
• 2. The GABA content per serving/per day (mg), which must not exceed the 500 mg ceiling;
• 3. A warning statement identifying the populations for whom the product is unsuitable;
• 4. Where the product is positioned as a health food, a "Blue Cap" approval number issued by the National Medical Products Administration (NMPA) must be obtained, and the label must fully display the approval number, suitable populations, unsuitable populations, precautions, and other legally required content; health benefit claims may not exceed the scope of what has been approved.

Chinese-Language Labels for Imported Products

Pursuant to Article 97 of the *Food Safety Law*, imported pre-packaged foods must bear a Chinese-language label complying with Chinese standards, and the information in the original-language label must not contradict the Chinese-language label. The Chinese-language declaration of GABA content must be consistent with the original-language version, and units of measurement must conform to China's statutory units of measurement.

1.3 United States: Structure/Function Claim Boundaries Under the DSHEA Framework

The United States regulates GABA supplements under the *Dietary Supplement Health and Education Act* of 1994 (DSHEA). No pre-market approval is required, but the following labeling obligations apply:

• Supplement Facts panel: Must list the amount per serving (mg) and the percentage of Daily Value (where applicable);
• Structure/function claims must be filed with the FDA within 30 days of going to market, and the label must include the disclaimer: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.";
• GMP compliance: 21 CFR Part 111 requires manufacturers to test ingredient quantities; labeled quantity values must be supported by testing data;
• GABA is not currently on the FDA's Generally Recognized as Safe (GRAS) list; companies marketing it as a new dietary ingredient (NDI) must submit a safety notification pursuant to 21 CFR 190.6.

1.4 European Union: The Dual Threshold of Novel Food and Health Claims

EU regulation of GABA is governed by two overlapping frameworks:

• 1. Novel Food Regulation (Regulation (EU) 2015/2283): Where GABA is determined to have no significant history of consumption within the EU prior to 15 May 2015, it must obtain novel food authorization before it may be placed on the market;
• 2. Health Claims Regulation (Regulation (EC) No 1924/2006): The European Food Safety Authority (EFSA) has not issued a positive scientific opinion on health claims for GABA; at present, GABA supplements on the markets of EU member states may not, in principle, carry authorized health claims.

---

II. Label Compliance Framework and Prohibited Areas

2.1 Dimensions That May Lawfully Appear on Labels

In any jurisdiction, the following information falls within the compliant dimensions of quantification and traceability:

• Content identification: The guaranteed measured GABA content per tablet/sachet/daily serving (mg);
• Ingredient origin and production method: Statements such as "obtained by lactic acid bacteria fermentation using glutamic acid as substrate" or "derived from germinated brown rice" are factual descriptions;
• Third-party testing certification: Report numbers issued by bodies such as JHNFA (Japan Health and Nutrition Food Association), NSF International, or Eurofins;
• GMP certification information: The name of the certifying body and the certification number for the GMP certification held by the manufacturing facility — verifiable quality system facts.

Taking as an example a product manufactured at a facility holding JHNFA GMP Conformity Certification (Certification No. 34225) under Kakumatsu Pharmaceutical / Showa, that certification number is cross-verifiable in the JHNFA official database. This constitutes publicly accessible compliant information disclosure, not a health claim.

2.2 Categories of Representations That Are Expressly Prohibited

2.3 How to Verify a Foods with Function Claims Notification

Consumers may independently verify whether a product has been lawfully notified by following these steps:

• 1. Access the Consumer Affairs Agency Foods with Function Claims notification search page;
• 2. Search by product brand name, company name, or notification number;
• 3. Confirm that the "Name of Functional Ingredient" (Kinōsei Kanyū Seibun-mei) in the notification summary is GABA, and that the daily intake is consistent with the actual product label;
• 4. Confirm that the notification status shows "Notified" (Todokede-zumi) — not withdrawn (Tettai) or returned (Sashimodoshi).

---

III. Compliance Considerations for Cross-Border Purchases

3.1 Chinese Consumers Purchasing GABA Products from Japan

Personal-Use Import Allowance

Pursuant to General Administration of Customs Announcement No. 26 of 2016 and cross-border e-commerce related policies, personally imported goods for personal use must fall within reasonable quantity limits. GABA supplements are ordinary health foods and are not pharmaceuticals; under normal circumstances, they may be declared upon entry as personal-use items, but bulk stockpiling may be classified as commercial importation, in which case commercial import procedures must be followed for customs clearance.

Chinese-Language Label Compliance

Imported foods entering China through cross-border e-commerce channels (pilot comprehensive pilot zone model) currently benefit from a label exemption arrangement (applicable only within the scope of pilot comprehensive pilot zones) but must be accompanied by an electronic Chinese-language description; those imported through general trade must bear a Chinese-language label complying with GB 7718. Consumers who receive products in original -language packaging without any Chinese-language description face a degree of compliance risk.

Ingredient Content Verification

Upon receipt, consumers should verify: whether the labeled GABA content falls within the ≤500 mg/day limit; whether the packaging identifies the unsuitable populations (infants and young children; pregnant women); and where such Chinese-language notifications are absent, priority should be given to products with a notification on record with the Consumer Affairs Agency and transparent ingredient quantity information.

3.2 U.S. Consumers Purchasing from Japan

FDA Import Rules

The U.S. FDA generally takes a permissive stance toward personal importation of food supplements for personal use (Personal Importation Policy), but products must meet the basic requirements of DSHEA and may not promote pharmaceutical uses. Labels must be in English or an English description must be available.

NDI Issue

Where GABA is determined to be a new dietary ingredient for the U.S. market, a consumer's purchase of a product for which no NDI notification has been submitted represents a compliance deficiency at the regulatory level; however, enforcement action is typically directed at manufacturers and importers rather than individual consumers.

3.3 Readability Verification of Third-Party Testing Reports

When assessing the credibility of ingredient quantities in cross-border products, consumers should look for the following verifiable elements:

• Testing body accreditation: The report-issuing organization should hold ISO/IEC 17025 accreditation;
• Testing method: GABA quantitative analysis is typically conducted by HPLC-UV or HPLC-fluorescence detector (FLD); the report should specify the method and limit of detection;
• Batch number traceability: The batch number stated in the testing report should be traceable to and correspond with the batch number on the physical product;
• Client information: The party that commissioned the report should be the product manufacturer or an authorized distributor, not an unrelated third party.

---

IV. Actionable Guidance for Consumers

• 1. Prioritize notified products: When purchasing GABA products in Japan, use the Consumer Affairs Agency FLD database to verify whether the product holds a valid Foods with Function Claims notification; the ingredient content stated in the notification represents a quantity guarantee on official record.
• 2. Check quantity limits: In consumption scenarios where the destination is mainland China, confirm that the GABA content per daily serving does not exceed 500 mg; products exceeding this level are not legally eligible for circulation on the Chinese market.
• 3. Verify GMP certification information: The GMP conformity certification status and validity period of the manufacturing facility can be checked on the JHNFA website; confirm the authenticity of the certification number to avoid products bearing fabricated certification information.
• 4. Avoid therapeutic language: Any product label that uses wording such as "treat," "prevent," "diagnose," or "cure" constitutes a violation in all major markets. The presence of such language is in itself a signal that the product does not meet compliance standards.
• 5. Retain proof of purchase: When purchasing cross-border products, it is advisable to retain the order record from the purchasing platform, photographs of the product batch number, and any testing reports provided by the seller, for subsequent traceability purposes.
• 6. Do not substitute price for compliance judgment: A high price does not equal high compliance, and a low price does not necessarily mean low quality. Transparency of ingredient quantity labeling, notification/certification status, and the accessibility of testing reports are objective dimensions for assessing the credibility of product information, and are unrelated to price.

---

Conclusion

The compliance foundation of GABA products lies in the quantifiability, traceability, and verifiability of ingredient content — not in any claims or promises regarding health outcomes. Japan's notification and public disclosure mechanism under the Foods with Function Claims system, China's daily use ceiling under the novel food ingredient regulations, the United States' mandatory Supplement Facts labeling requirement under DSHEA, and the EU's novel food approval framework together constitute the institutional safeguards that different markets have established for information transparency in GABA products.

For cross-border consumers, familiarity with the key quantitative standards and compliance verification pathways in the jurisdictions described above is a foundational tool for making rational decisions in an environment of information asymmetry. In the stages of label design and market access, manufacturers should likewise treat "labeling compliance before health effect promotion" as an inviolable red line, and build long-term brand credibility through transparency of quantitative data.

---

*This article is for informational purposes only and does not constitute legal, medical, or investment advice. Regulatory provisions are time-sensitive; readers should verify the current version of any provisions cited before making commercial or consumer decisions.*